why BioCryst Pharmaceuticals Inc. [BCRX] is a Good Choice for Investors After New Price Target of $18.60

BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] price surged by 0.56 percent to reach at $0.08. The company report on August 18, 2022 that BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Saudi Arabia.

“There is a significant need for new treatment options for HAE in Saudi Arabia. With this approval, we continue to deliver on our commitment to bringing our oral, once-daily prophylactic therapy to as many HAE patients around the world as possible,” said Charlie Gayer, chief commercial officer of BioCryst.

A sum of 2107140 shares traded at recent session while its average daily volume was at 3.10M shares. BioCryst Pharmaceuticals Inc. shares reached a high of $14.39 and dropped to a low of $14.105 until finishing in the latest session at $14.33.

The one-year BCRX stock forecast points to a potential upside of 22.96. The average equity rating for BCRX stock is currently 2.30, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on BioCryst Pharmaceuticals Inc. [BCRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $18.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on August 05, 2022. The new note on the price target was released on August 05, 2022, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $22 to $13, while Barclays kept a Equal Weight rating on BCRX stock. On April 11, 2022, analysts decreased their price target for BCRX shares from 21 to 14.

The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.68, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 12.85.

BCRX Stock Performance Analysis:

BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.28. With this latest performance, BCRX shares gained by 20.12% in over the last four-week period, additionally sinking by -27.48% over the last 6 months – not to mention a drop of -1.65% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 66.38, with the RSI for the last a single of trading hit 65.92, and the three-weeks RSI is set at 64.51 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 11.59, while it was recorded at 14.53 for the last single week of trading, and 12.89 for the last 200 days.

Insight into BioCryst Pharmaceuticals Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -113.08 and a Gross Margin at +94.88. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -117.11.

BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 5.20.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 15.20%.

BioCryst Pharmaceuticals Inc. [BCRX] Insider Position Details

There are presently around $2,149 million, or 74.00% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 13,987,418, which is approximately -0.812% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 13,810,173 shares of the stock with an approximate value of $197.9 million in BCRX stocks shares; and BAKER BROS. ADVISORS LP, currently with $182.15 million in BCRX stock with ownership of nearly 0% of the company’s market capitalization.

Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 116 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 41,463,508 shares. Additionally, 114 investors decreased positions by around 18,603,183 shares, while 45 investors held positions by with 89,892,655 shares. The mentioned changes placed institutional holdings at 149,959,346 shares, according to the latest SEC report filing. BCRX stock had 44 new institutional investments in for a total of 15,496,583 shares, while 54 institutional investors sold positions of 10,036,218 shares during the same period.


Please enter your comment!
Please enter your name here